Extended BRAT eating can actually worsen nutritional status and delay gut adaptation
Pinch firmly enough to lift the tissue but not so hard that you cause pain from the pinch itself
It is known that the CV protection effect of GLP-1RAs have been proven through eight large-scale clinical studies, including Evaluation of LIXisenatide in Acute coronary syndrome (ELIXA) [66], LEADER [44], Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN)-6 [67], Exenatide Study of Cardiovascular Event Lowering (EXSCEL) [68], Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes) [69], Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) [70], Peptide Innovation for Early Diabetes Treatment (PIONEER) 6 [67,71], and AMPLITUDE-O [51]
These drugs mimic the action of glucagon-like peptide-1, a hormone naturally produced in our intestines
The concurrent GLP-1 and GIP arms drive glucose-dependent insulin secretion that offsets glucagon-induced gluconeogenesis, producing net euglycaemia alongside elevated lipolysis (Jastreboff et al., NEJM, 2023) [1]
Understanding GLP-1 Medications and Their Benefits What Are GLP-1 Medications
